HK Stock Market Move | Concept stocks in the CRO sector continue to rise. VIVA BIOTECH (01873) rose nearly 10%, while Pharmaron Beijing (03759) rose over 9%.

CRO concept stocks continue to rise, as of the time of publication, VIVA BIOTECH (01873) rose by 9.72% to HK$1.58; Pharmaron Beijing (03759) rose by 9.43% to HK$19.04; Hangzhou Tigermed Consulting (03347) rose by 7.45% to HK$38.2; WUXI BIO (02269) rose by 5.76% to HK$25.7; WuXi AppTec (02359) rose by 5.74% to HK$69.95. In recent news, Pharmaron Beijing announced that it has completed the acquisition of Haixin Zhixihui. This transaction signifies Kanglong Clinical's expansion to provide high-quality personalized patient management services by integrating Haixin Zhixihui's high-quality and compliant patient data and AI technology platform. Apart from Pharmaron Beijing, many CRO companies have started to invest in AI. VIVA BIOTECH recently announced the deployment of the DeepSeek-R1 model locally to further enhance intelligent workflow. VIVA BIOTECH stated that the company started building the AIDD/CADD platform at the beginning of the AI wave. Hangzhou Tigermed Consulting also mentioned that besides the MedTrans smart translation platform, the company is actively embracing artificial intelligence technology to develop and deploy more AI innovative application platforms. Guotou Securities stated that with the improvement in the success rate of AI-led drug development projects and continuous progress in related R&D pipelines, the further commercial application of AI pharmaceutical technology is worth looking forward to. Traditional CRO companies are following the industry development trends by establishing AI technology platforms to enhance the R&D efficiency of their existing businesses, empowering drug development for their clients better. As the application capabilities of AI technology continue to improve in various stages of drug development, the progress of AI pharmaceutical technology and the release of related new platforms from various CRO companies are worth anticipating.